Dupilumab Approved for Bullous Pemphigoid

"

On June 20, 2025, the U.S. FDA granted a landmark approval for a new treatment targeting a rare autoimmune skin condition. This decision brings the first therapy designed specifically to address the root cause of the challenging and often debilitating illness, offering relief to roughly 27,000 adults in the U.S. who struggle with uncontrolled symptoms.